Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Invested Capital (2016 - 2025)

Dexcom (DXCM) has disclosed Invested Capital for 16 consecutive years, with $2.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 30.6% to $2.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 billion, a 30.6% increase, with the full-year FY2025 number at $2.7 billion, up 30.6% from a year prior.
  • Invested Capital was $2.7 billion for Q4 2025 at Dexcom, up from $2.7 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $2.7 billion in Q4 2025 to a low of $1.6 billion in Q1 2021.
  • A 5-year average of $2.2 billion and a median of $2.2 billion in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 76.01% in 2021, then fell 14.59% in 2022.
  • Dexcom's Invested Capital stood at $2.0 billion in 2021, then grew by 4.39% to $2.1 billion in 2022, then dropped by 2.96% to $2.1 billion in 2023, then increased by 1.64% to $2.1 billion in 2024, then soared by 30.6% to $2.7 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Invested Capital are $2.7 billion (Q4 2025), $2.7 billion (Q3 2025), and $2.6 billion (Q2 2025).